Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,779,938
-
Total 13F shares
-
47,101,751
-
Share change
-
-955,206
-
Total reported value
-
$399,477,630
-
Put/Call ratio
-
22%
-
Price per share
-
$8.48
-
Number of holders
-
129
-
Value change
-
-$8,156,185
-
Number of buys
-
63
-
Number of sells
-
59
Institutional Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q2 2024
As of 30 Jun 2024,
Theravance Biopharma, Inc. - Common Stock (TBPH) was held by
129 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,101,751 shares.
The largest 10 holders included
Madison Avenue Partners, LP, Weiss Asset Management LP, BAUPOST GROUP LLC/MA, BlackRock Inc., Irenic Capital Management LP, Newtyn Management, LLC, VANGUARD GROUP INC, Park West Asset Management LLC, STATE STREET CORP, and Oasis Management Co Ltd..
This page lists
129
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.